drugset / Trial / NCT00637845

Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)

NCT00637845

Phase 4 Completed 248 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD) with continued heartburn symptoms with a course of therapy of 30 mg twice daily Lansoprazole.

Timeline

Start
2002-06
Primary completion
2003-02
Completion
2003-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg
Comparator Lansoprazole Other / unclassified 30 mg